dm+d

108461005

Medicine Compliance Aid Stability

ZanaflexCephalon (UK) Ltd

Cephalon (UK) Ltd
Zanaflex
Tablets 2mg, 4mg
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
Airtight container
Airtight container.
29 January 2015

genericActavis UK Ltd

Actavis UK Ltd
generic
Tablets 2mg, 4mg
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
Airtight container
Airtight container.
29 January 2015

Lactation Safety Information

Baclofen
Moderate milk levels anticipated due to the drug's properties
No published evidence of safety
Monitor infant’s liver function and for signs of sedation
24 September 2020

New Medicines

TizasprayLower back pain

Information

Tizaspray
New formulation
MDM SpA

Development and Regulatory status

None
Phase III Clinical Trials
None

Category

Skeletal muscle relaxant tha stimulates alpha‐2 adrenergic receptors in the central nervous system, inhibiting presynaptic release of norepinephrine and increasing the inhibitory effect on alpha motor neurons and motor reflexes.
Back pain is extremely common. 60-80% of people in the UK report back pain at some time in their lives. A UK population-based cross-sectional study of people aged 25 years and older found the one-month period prevalence of low back pain to be around 30%, peaking at age 41-50 years. The one-year prevalence of chronic low back pain is about 1% [1].
Lower back pain
Intranasal

Evidence based evaluations